Tag: Promomed Group

Price War in the Weight Loss Market: PROMOMED Cuts Tirzetta Cost Following GEROPHARM

The Russian market for obesity and diabetes therapies has entered a phase of intense competition. On February 13, 2026,...

500 Million Rubles for Pet Health: PROMOMED Launches Substitute for Scarce “Onsior”

Russian pharmaceutical company "PROMOMED — Animal Health" has announced the registration and launch of full-cycle production of a new...

The Medsintez Plant has launched a full-cycle production of hypoglycemic drugs for treating type II diabetes mellitus

In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease.

PROMOMED obtained permission to produce drug product for diabetes mellitus Kvinsenta with semaglutide

The Russian government has published an order authorizing PROMOMED GROUP to use inventions protected by patents of the Danish company Novo Nordisk related to a drug product with semaglutide for the treatment of diabetes mellitus.

New product from Promomed Group for protection, ensure the functioning and repair of the nervous system cells

Promomed Group has registered a new drug Brainmax®, reaffirming its commitment to the strategy of launching innovative, knowledge-based products....

The new direct acting anticoagulant in the anticovid portfolio of Promomed Group

Promomed Group received marketing authorization certificate for a medicinal product with nadroparin calcium as active ingredient. Nadroparin is a...

Russian Ministry of Health included injectable Areplivir® in the guidelines for the treatment of COVID-19

The Ministry of Health of the Russian Federation has included the injectable form of the direct-acting antiviral drug Areplivir® (favipiravir)...

Biokhimik JSC of Promomed Group and Mordovia State University agreed on further cooperation

At the meeting of the management of Biokhimik JSC with Acting Rector of the Ogarev Mordovia State University Dmitry...

M. Smagin: a competent system of joint planning of drugs procurements by the government and pharmaceutical business will eliminate possible shortages

In his speech at the «360 degree Pharmaceutical Supply» conference, Maxim Smagin, General Director of Promomed Group said: The...

Kira Zaslavskaya: we need joint and responsible work of all participants in the pharmaceutical market

«Vision and participation are essential to address global pharmaceutical safety challenges, including the fight against the pandemic. This means...

Efficacy of Areplivir (favipiravir) in the treatment of COVID-19 discussed at the 16th Russian Congress of Internal Medicine

On the first day of the 16th Russian Congress of Internal Medicine, Promomed Group organized a satellite symposium «Always...

The first Russian injectable drug for treatment of COVID-19 is ap-proved

The first Russian direct-acting intravenous antiviral drug Areplivir® (favipiravir) received marketing authorization certificate and its supply to hospitals in...